Biotech RadarJobs updated

COMPANY

BeBetter Med

bebettermed.com ↗

Clinical Phase 3

Profile checked Oct 10, 2026

Keywords: Relapsed/Refractory Diffuse Large B-Cell Lymphoma Non Small Cell Lung Cancer KRAS G12C Mutation Polycythemia Vera Advanced Breast Cancer Relapsed or Refractory Diffuse Large B-cell Lymphoma Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol Advanced Triple-Negative Breast Cancer Locally Advanced Triple-negative Breast Cancer Metastatic Triple-negative Breast Cancer Previously Untreated Peripheral T-Cell Lymphoma Metastatic Breast Cancer HR+/HER2- Locally Advanced EGFR Exon 20 Insertion Mutation Relapsed or Refractory Non-Hodgkin's Lymphoma Relapsed or Refractory Multiple Myeloma BEBT-209 BEBT-908 BEBT-607Tablets BEBT-507 BEBT-701 BEBT-109 BEBT-503

15Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) source ↗
  2. Trial start Phase 2/Phase 3: A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer source ↗
  3. Trial start Phase 1/Phase 2: A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C） source ↗
  4. Trial start Phase 1: Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV) source ↗
  5. Trial start Phase 3: Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma source ↗
  6. Trial start Phase 2: Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations source ↗
  7. Trial start Phase 1: Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma source ↗
  8. Trial start Phase 1: Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation source ↗
  9. Trial start Phase 2: A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer source ↗
  10. Trial start Phase 1: Study of Orally Administered BEBT-503 in Healthy Subjects source ↗
  11. Trial start Phase 3: Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed Af source ↗
  12. Trial start Phase 2: Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer source ↗
  13. Trial start Phase 2: Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects source ↗
  14. Trial start I: Phase I Study of BEBT-209 in Women With Advanced Breast Cancer source ↗
  15. Trial start Phase 1: Study of BEBT-908 in Subjects With Advanced Hematological Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 15

RecordTitlePhaseStatusStartPrimary completion
NCT06792253Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaPhase 3RecruitingJan 6, 2025Dec 31, 2028 (estimated)
NCT06117371Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C MutationPhase 1CompletedSep 18, 2023Oct 29, 2024 (actual)
NCT07012109Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)Phase 1RecruitingJun 17, 2025Jan 31, 2028 (estimated)
NCT06047184Phase I Study of BEBT-209 in Women With Advanced Breast CancerICompletedJul 15, 2019Jan 30, 2024 (actual)
NCT06074107Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma SubjectsPhase 2CompletedJun 12, 2020Jul 17, 2023 (actual)
NCT07368608A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C）Phase 1/Phase 2RecruitingMar 1, 2026Nov 30, 2028 (estimated)
NCT06514027Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion MutationsPhase 2RecruitingAug 28, 20242027-06 (estimated)
NCT06685796A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast CancerPhase 2CompletedApr 12, 2023Apr 20, 2026 (actual)
NCT07544056A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast CancerPhase 2/Phase 3RecruitingJun 4, 20262030-06 (estimated)
NCT07676175A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)Phase 2Not yet recruitingJul 1, 2026Jan 31, 2028 (estimated)
NCT06998108Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine TherapyPhase 3RecruitingJun 9, 2022Dec 31, 2025 (estimated)
NCT06706713Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung CancerPhase 2RecruitingApr 15, 2022Dec 31, 2025 (estimated)
NCT06164327Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaPhase 1Unknown status (ClinicalTrials.gov)Dec 1, 2023Oct 31, 2025 (estimated)
NCT06082596Study of BEBT-908 in Subjects With Advanced Hematological TumorsPhase 1CompletedMar 2, 2016Mar 8, 2019 (actual)
NCT05391880Study of Orally Administered BEBT-503 in Healthy SubjectsPhase 1CompletedAug 26, 2022May 29, 2023 (actual)
Feedback